EULAR/PReS recommendations for the diagnosis and management of Still’s disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still’s disease

Systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD) are considered the same disease, but a common approach for diagnosis and management is still missing. Methods In May 2022, EULAR and PReS endorsed a proposal for a joint task force (TF) to develop recommendations for the diagnosis and management of sJIA and AOSD. The TF agreed during a first meeting to address four topics: similarity between sJIA and AOSD, diagnostic biomarkers, therapeutic targets and strategies and complications including macrophage activation syndrome (MAS). Systematic literature reviews were conducted accordingly. Results The TF based their recommendations on four overarching principles, highlighting notably that sJIA and AOSD are one disease, to be designated by one name, Still’s disease. Fourteen specific recommendations were issued. Two therapeutic targets were defined: clinically inactive disease (CID) and remission, that is, CID maintained for at least 6 months. The optimal therapeutic strategy relies on early use of interleukin (IL-1 or IL-6 inhibitors associated to short duration glucocorticoid (GC). MAS treatment should rely on high-dose GCs, IL-1 inhibitors, ciclosporin and interferon-γ inhibitors. A specific concern rose recently with cases of severe lung disease in children with Still’s disease, for which T cell directed immunosuppressant are suggested. The recommendations emphasised the key role of expert centres for difficult-to-treat patients. All overarching principles and recommendations were agreed by over 80% of the TF experts with a high level of agreement. Conclusion These recommendations are the first consensus for the diagnosis and management of children and adults with Still’s disease.

• Publication year

  2024

• Venue

  Annals of the Rheumatic Diseases

• Publication date

  2024-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/ard-2024-225851PMID 39317417PMCID 11672000
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Systemic juvenile idiopathic arthritis and adult-onset Still’s disease are the same disease: evidence from systematic reviews and meta-analyses informing the 2023 EULAR/PReS recommendations for the diagnosis and management of Still’s disease

  2024cited by this paper
• Type I interferon signature and cycling lymphocytes in macrophage activation syndrome

  2023cited by this paper
• Development of a Screening Algorithm for Lung Disease in Systemic Juvenile Idiopathic Arthritis

  2023cited by this paper
• The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS)

  2023influential reference
• The administration of methotrexate in patients with Still's disease, "real-life" findings from AIDA Network Still Disease Registry.

  2023cited by this paper
• Recombinant Interleukin‐1 Receptor Antagonist Is an Effective First‐Line Treatment Strategy in New‐Onset Systemic Juvenile Idiopathic Arthritis, Irrespective of HLA‐DRB1 Background and IL1RN Variants

  2023cited by this paper
• POS0277 SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS ASSOCIATED LUNG DISEASE IN EUROPE

  2023cited by this paper
• JAK inhibitors in systemic juvenile idiopathic arthritis

  2023cited by this paper
• Rescue of Pap-Mas in Systemic JIA Using Janus Kinase Inhibitors, Case Report and Systematic Review

  2023cited by this paper
• A novel serum calprotectin (MRP8/14) particle-enhanced immuno-turbidimetric assay (sCAL turbo) helps to differentiate systemic juvenile idiopathic arthritis from other diseases in routine clinical laboratory settings

  2023cited by this paper
• Part 5: Allogeneic HSCT in refractory SJIA with lung disease; recent cases from centers in North America & Europe

  2023cited by this paper
• The Conundrum of Lung Disease and Drug Hypersensitivity‐like Reactions in Systemic Juvenile Idiopathic Arthritis

  2022cited by this paper
• Systemic Juvenile Idiopathic Arthritis/Pediatric Still’s Disease, a Syndrome but Several Clinical Forms: Recent Therapeutic Approaches

  2022cited by this paper
• Latent class analysis of 216 patients with adult-onset Still’s disease

  2022cited by this paper
• Identification of Distinct Inflammatory Programs and Biomarkers in Systemic Juvenile Idiopathic Arthritis and Related Lung Disease by Serum Proteome Analysis

  2022cited by this paper
• Greetings from the editor 2023

  2022cited by this paper
• Efficacy and safety of emapalumab in macrophage activation syndrome

  2022cited by this paper
• Improving Diagnosis and Clinical Management of Acquired Systemic Autoinflammatory Diseases

  2022cited by this paper
• AOSD Endotypes based on immune cell profiles: patient stratification with hierarchical clustering analysis.

  2022cited by this paper
• Implementation of recommendations in rheumatic and musculoskeletal diseases: considerations for development and uptake

  2022cited by this paper
• POS0339 POINTS TO CONSIDER AT THE EARLIEST STAGES OF THE DIAGNOSIS AND MANAGEMENT OF HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS/MACROPHAGE ACTIVATION SYNDROME (HLH/MAS)

  2022cited by this paper
• JAK inhibitors in difficult-to-treat adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis.

  2022cited by this paper
• Refractory systemic onset juvenile idiopathic arthritis: current challenges and future perspectives

  2022cited by this paper
• The clinical heterogeneity of adult onset Still's disease may underlie different pathogenic mechanisms. Implications for a personalised therapeutic management of these patients.

  2022cited by this paper
• The role of cytokines and their antagonists in the treatment of COVID‐19 patients

  2022cited by this paper
• Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis

  2021cited by this paper
• Clinical phenotypes and prognostic factors of adult-onset Still’s disease: data from a large inpatient cohort

  2021cited by this paper
• Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 alleles

  2021cited by this paper
• IL-1β–driven osteoclastogenic Tregs accelerate bone erosion in arthritis

  2021cited by this paper
• Looking beyond VEXAS: Coexistence of undifferentiated systemic autoinflammatory disease and myelodysplastic syndrome.

  2021cited by this paper
• Catastrophic adult-onset Still’s disease as a distinct life-threatening clinical subset: case–control study with dimension reduction analysis

  2021cited by this paper
• Fever of Unknown Origin (FUO) - a call for new research standards and updated clinical management.

  2021cited by this paper
• IL-1β-driven osteoclastogenic T regulatory cells accelerate bone erosion in arthritis.

  2021cited by this paper
• Biological classification of childhood arthritis: roadmap to a molecular nomenclature

  2021cited by this paper
• Efficacy of Moderately Dosed Etoposide in Macrophage Activation Syndrome–Hemophagocytic Lymphohistiocytosis

  2021cited by this paper
• Dissecting the clinical heterogeneity of adult-onset Still's disease, results from a multi-dimensional characterisation and stratification.

  2021cited by this paper
• Effectiveness and safety of ruxolitinib for the treatment of refractory systemic idiopathic juvenile arthritis like associated with interstitial lung disease : a case report

  2020cited by this paper
• Low dose ruxolitinib plus HLH-94 protocol: A potential choice for secondary HLH.

  2020cited by this paper
• Th17 reprogramming of T cells in systemic juvenile idiopathic arthritis.

  2020cited by this paper
• Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome

  2020cited by this paper
• Systemic autoinflammatory diseases: Clinical state of the art.

  2020cited by this paper
• Immunopathology of SARS-CoV-2 Infection: Immune Cells and Mediators, Prognostic Factors, and Immune-Therapeutic Implications

  2020cited by this paper
• Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis.

  2020cited by this paper
• Cardiac involvement in adult-onset Still's disease: Manifestations, treatments and outcomes in a retrospective study of 28 patients.

  2020cited by this paper
• A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process

  2020cited by this paper
• Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease.

  2020cited by this paper
• Early Treatment and IL1RN Single‐Nucleotide Polymorphisms Affect Response to Anakinra in Systemic Juvenile Idiopathic Arthritis

  2020cited by this paper
• Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis

  2019cited by this paper
• Systemic Juvenile Idiopathic Arthritis and Adult Onset Still Disease

  2019cited by this paper
• Emergent high fatality lung disease in systemic juvenile arthritis

  2019cited by this paper
• Systemic Juvenile Idiopathic Arthritis–Associated Lung Disease: Characterization and Risk Factors

  2019cited by this paper
• Treatment to Target Using Recombinant Interleukin‐1 Receptor Antagonist as First‐Line Monotherapy in New‐Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five‐Year Follow‐Up Study

  2019cited by this paper
• Macrophage Activation Syndrome in Patients Affected by Adult-onset Still Disease: Analysis of Survival Rates and Predictive Factors in the Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale Cohort

  2018cited by this paper
• Mechanisms, biomarkers and targets for adult-onset Still’s disease

  2018cited by this paper
• Massive increase in monocyte HLA-DR expression can be used to discriminate between septic shock and hemophagocytic lymphohistiocytosis-induced shock

  2018cited by this paper
• Complications of adult-onset Still’s disease and their management

  2018cited by this paper
• Autoimmune manifestations associated with myelodysplastic syndromes

  2018cited by this paper
• Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany

  2018cited by this paper
• Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis

  2018cited by this paper
• Diagnostic and management of life-threatening Adult-Onset Still Disease: a French nationwide multicenter study and systematic literature review

  2018cited by this paper
• Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus

  2018cited by this paper
• Proinflammatory Cytokine Environments Can Drive Interleukin‐17 Overexpression by γ/δ T Cells in Systemic Juvenile Idiopathic Arthritis

  2017cited by this paper
• Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 cases collected in 2 rheumatologic centers.

  2017cited by this paper
• Macrophage activation syndrome in Still’s disease: analysis of clinical characteristics and survival in paediatric and adult patients

  2017cited by this paper
• Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis

  2016cited by this paper
• 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis

  2016cited by this paper
• Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial*

  2016cited by this paper
• Gene-expression analysis of adult-onset Still’s disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity

  2015cited by this paper
• Management of juvenile idiopathic arthritis: hitting the target

  2015cited by this paper
• Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic Syndrome

  2014influential reference
• 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations

  2014cited by this paper
• Patients with Very Early-onset Systemic Juvenile Idiopathic Arthritis Exhibit More Inflammatory Features and a Worse Outcome

  2013cited by this paper
• Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis

  2013cited by this paper
• C reactive protein may not be reliable as a marker of severe bacterial infection in patients receiving tocilizumab

  2013cited by this paper
• Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.

  2012cited by this paper
• Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.

  2012cited by this paper
• Consensus treatment plans for new‐onset systemic juvenile idiopathic arthritis

  2012cited by this paper
• A new era in the treatment of systemic juvenile idiopathic arthritis.

  2012cited by this paper
• Glucocorticoids in systemic lupus erythematosus.

  2011cited by this paper
• American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis

  2011cited by this paper
• AGREE II: advancing guideline development, reporting and evaluation in health care.

  2010cited by this paper
• Indications of glucocorticoids in early arthritis and rheumatoid arthritis: recommendations for clinical practice based on data from the literature and expert opinion.

  2010cited by this paper
• Clinical Manifestations but not Cytokine Profiles Differentiate Adult-onset Still’s Disease and Sepsis

  2010cited by this paper
• HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis

  2007cited by this paper
• University

  2006cited by this paper
• International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001.

  2004cited by this paper
• [Immunology and allergy].

  2003cited by this paper
• Proposal for a New Set of Classification Criteria for Adult-Onset Still Disease

  2002cited by this paper
• Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis.

  2000cited by this paper
• Rheumatology

  1995cited by this paper
• Preliminary criteria for classification of adult Still's disease.

  1992cited by this paper
• Internal medicine.

  1980cited by this paper
• On a Form of Chronic Joint Disease in Children.

  1978cited by this paper
• Heberden Oration, 1977. Chronic arthritis in childhood.

  1978cited by this paper
• Still's disease in the adult.

  1971cited by this paper
• Children in Hospital

  1958cited by this paper

• NOD2-Related Multisystem Inflammatory Disorders and Recent Advances

  2026cites this paper
• Type I interferon signature associates with lung disease, drug-associated immune reactions, and genetic variation in interferon-linked pathways in Still's disease.

  2026cites this paper
• IL-18 and the Quest for the Holy Grail (in Still's Disease).

  2026cites this paper
• Experience Of Colchicine Administration in Refractory Still’s Disease

  2026cites this paper
• Transition of serum-free IL-18 levels in systemic juvenile idiopathic arthritis measured by a novel detection method.

  2026cites this paper
• Adult-onset Still’s disease presenting with progressive motor neuropathy

  2026cites this paper
• Successful treatment association of interleukin-1 inhibitor anakinra and Janus kinase inhibitor baricitinib in Still's disease.

  2026cites this paper
• Pharmacologic management of renal involvement in monogenic autoinflammatory diseases

  2026cites this paper
• Use of biologic drugs in juvenile idiopathic arthritis patients followed in an adult rheumatology clinic: real-life data from the HUR-BIO biologic registry

  2026cites this paper
• Global burden and genetic insights of RA and JIA in ages 0–19 years: GBD 2021 and MR analysis

  2026cites this paper
• Evaluation of adalimumab tapering regimens in children and adolescents with juvenile idiopathic arthritis in remission: a simulation study

  2026cites this paper
• Identification of potential diagnostic biomarkers for systemic juvenile idiopathic arthritis by integrative transcriptomic analysis.

  2026cites this paper
• Reassessing the prevalence of monophasic, polyphasic and persistent disease courses in still's disease.

  2026cites this paper
• Autoimmunity, autoinflammation, and the cardiovascular system: immunopathogenesis and targeted therapy

  2026cites this paper
• Safety and Effectiveness of Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis in Japan: A Post-Marketing Surveillance Study.

  2026cites this paper
• Favorable coronary outcomes following IL-6 blockade with tocilizumab in IVIG-resistant kawasaki disease: a case series

  2026cites this paper
• Therapeutic management of inflammatory heart diseases.

  2026cites this paper
• Still’s Disease and Autoinflammation: Positioning an Inflammatory Syndrome on the Autoinflammation-Autoimmunity Spectrum

  2026influential citation
• No association of HLA-DRB1*15:01 and HLA-DRB1*11 in systemic juvenile idiopathic arthritis-associated macrophage activation syndrome and other secondary hemophagocytic lymphohistiocytoses

  2026cites this paper
• Síndrome de activación macrofágica en relación a enfermedad de Still. Una combinación potencialmente mortal

  2025cites this paper
• Advancing multidisciplinary management of pediatric hyperinflammatory disorders

  2025cites this paper
• Neutrophilic Urticarial Dermatosis: A Window into Systemic Inflammation and Autoimmune Disorders

  2025cites this paper
• Elevated serum levels of interleukin-18 discriminate Still’s disease from other autoinflammatory conditions: results from the European ImmunAID cohort

  2025cites this paper
• Innate Lymphoid Cell Phenotypic and Functional Alterations in Patients With Systemic Juvenile Idiopathic Arthritis

  2025cites this paper
• Modeling the HLH immune synapse uncovers critical roles for IS termination, cytokine intensity, and target cell death.

  2025cites this paper
• The use of IL-1 and IL-6 inhibitors should be prioritised in Still's disease.

  2025cites this paper
• The use of IL-1 and IL-6 inhibitors should be prioritised in Still's disease - Authors' reply.

  2025cites this paper
• Endogenous Lipoid Pneumonia in Adult Autoinflammatory Disease

  2025cites this paper
• Pulmonary arterial hypertension in adults with Still's disease: another pulmonary manifestation associated with HLA-DRB1*15.

  2025cites this paper
• Adult-Onset Still’s Disease with Dermatomyositis-Like Lesions

  2025influential citation
• Insights from the 2024 pediatric rheumatology basic/translational years in review

  2025cites this paper
• Tofacitinib in the Treatment of Refractory Adult-Onset Still’s Disease Co-diagnosed With Celiac Disease: A Case Report

  2025cites this paper
• Impact of Interleukin‐1 Blockade on the Development of Macrophage Activation Syndrome in Still Disease: Incidence and Diagnostic Validity of the EULAR/ACR/PRINTO 2016 MAS Classification Criteria

  2025cites this paper
• Canakinumab treatment patterns in sJIA, FMF, TRAPS, and MKD/HIDS: real-world insights from a Belgian non-interventional study

  2025influential citation
• IL-6R blockade combined with immunosuppressants alleviates adult-onset Still’s disease through immune remodeling: a mass cytometry study

  2025influential citation
• Konsentierte Empfehlungen zu Diagnose und Management von sJIA und AOSD als „Still‘s disease“

  2025cites this paper
• Serum cytokine levels towards precision medicine in Still’s disease: a subanalysis of a randomized controlled trial of tocilizumab

  2025cites this paper
• Differential diagnosis of chronic spontaneous urticaria.

  2025cites this paper
• Evaluation of clinical biomarkers for differential diagnosis of intravascular lymphoma and Still’s disease

  2025cites this paper
• Worldwide evaluation of Clinical Practice Strategies (CliPS) for lung involvement in Still’s disease within the JIR-CliPS network: a COST action

  2025cites this paper
• Still's Lung Disease: Time to Recognize This Complication in Adults

  2025cites this paper
• Juvenile Idiopathic Arthritis.

  2025cites this paper
• Multimodal induction of fulminant HLH by IL-18 includes virus-specific NK immunodeficiency

  2025cites this paper
• Exposure during pregnancy to Il-1 targeted therapies and pregnancy, fetal and neonatal outcomes: a study from the French Teratology Information Service.

  2025cites this paper
• Utility of patient-reported outcomes for pulmonary symptoms and sleep disturbance and impairment in children with systemic juvenile idiopathic arthritis

  2025cites this paper
• Adult-Onset Still’s Disease in a 49-Year-Old Female in the UAE: A Case Report and Literature Review

  2025cites this paper
• Managing the clinical heterogeneity of patients with still's disease, from early diagnosis to timely treatment.

  2025cites this paper
• Current evidence on switching between biologic therapies for Still's disease: A systematic literature review.

  2025cites this paper
• Clinical use of biologics in juvenile idiopathic arthritis: lessons learned from real-world studies

  2025cites this paper
• Successful management of Still’s disease with severe liver injury through the administration of baricitinib: a case report

  2025cites this paper
• Chronic urticaria and autoinflammatory syndromes.

  2025cites this paper
• Therapieintensivierung in der Rheumatologie am Beispiel der nicht-systemischen juvenilen idiopathischen Arthritis: die Sicht der Pharmakologie

  2025cites this paper
• Diagnostic Dilemma: Adult Onset Still's Disease Mimicking Lymphoma—A Case Report and Literature Review

  2025cites this paper
• The evolving landscape of rheumatic drugs and their indications in paediatric and adolescent care

  2025cites this paper
• Traditional laboratory parameters and IFNγ-related biomarkers in the diagnosis and management of MAS.

  2025cites this paper
• Fever and inflammation of unknown origin in the 21st century.

  2025cites this paper
• Long-Term Safety of Anti-Interleukin-1 Medications in Children with Rheumatic Diseases: a Systematic Review

  2025cites this paper
• Adult onset cryopyrin-associated periodic syndrome due to germline missense mutation in NLRP3 in a previously healthy middle-aged woman

  2025cites this paper
• Aktuelle Diagnostik und Therapie des adulten Still-Syndroms

  2025cites this paper
• Correspondence on: Pulmonary arterial hypertension in adults with Still's disease: another pulmonary manifestation associated with HLA-DRB1*15-reply.

  2025cites this paper
• Whip-like rash on the trunk

  2025cites this paper
• Adult-onset Still's disease following COVID-19: A case report and literature review.

  2025cites this paper
• Comparative Efficacy and Safety of Anakinra and Canakinumab in Patients With VEXAS Syndrome: An International Multicenter Study

  2025cites this paper
• Identification of core genes in systemic juvenile idiopathic arthritis based on 113 machine learning algorithms

  2025cites this paper
• Glucocorticoids in rheumatic diseases. Part I

  2025cites this paper
• Clinical Features and Outcome Measures Across Still Disease (Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still Disease) Cohorts Worldwide: A Systematic Literature Review

  2025cites this paper
• Early IL‐1 Inhibition in Still's Disease: A Window of Opportunity for Improving Outcomes

  2025influential citation
• Enfermedad de Still del adulto

  2025cites this paper
• Response to correspondence on: Pulmonary arterial hypertension in adults with Still's disease: another pulmonary manifestation associated with HLA-DRB1*15.

  2025cites this paper
• Evaluating the Divide Between Patients’ and Physicians’ Perceptions of Adult-Onset Still’s Disease Cases: Insights from the PRO-AOSD Survey

  2025cites this paper
• Successful Treatment of Severe Purpura Fulminans With Anakinra.

  2025cites this paper
• Still’s disease: bridging the gap between guidelines and clinical practice

  2025cites this paper
• Biologic and targeted synthetic DMARD safety in inflammatory arthritis: British Society for Rheumatology guideline scope

  2025cites this paper
• Exploring pediatric onset Still’s disease patient journey and parental perceptions in Türkiye through a survey

  2025cites this paper
• Updates on the pathogenesis and molecular-targeted therapies of Still's disease.

  2025cites this paper
• Strong inhibition of IL-6 signal is clinically and serologically effective in refractory adult-onset Still's disease.

  2025cites this paper
• The progression of initial symptoms and its relationship with the clinical course in adult-onset Still’s disease: from the KEIO-AOSD cohort

  2025cites this paper
• Juvenile idiopathische Arthritis – Diagnose und Management

  2025cites this paper
• Clinical significance of non-infectious procalcitonin elevation in Still's disease: A predictor of macrophage activation syndrome.

  2025cites this paper
• Emapalumab as a Life-Saving Therapy for Macrophage Activation Syndrome in Refractory Systemic Juvenile Idiopathic Arthritis with Trisomy 21

  2025cites this paper
• Serum calprotectin in immune-mediated inflammatory rheumatic diseases: a new biomarker of inflammation

  2025cites this paper
• Vitesse de sédimentation : un marqueur dépassé ou toujours d’actualité ?

  2025cites this paper
• Pan American League of Associations for Rheumatology treatment recommendations for systemic juvenile idiopathic arthritis

  2025influential citation
• Pharmacological and non-pharmacological treatments for refractory paediatric Still’s disease: a scoping review

  2025cites this paper
• CD14+CXCL10+ monocytes are associated with peripheral immune network alterations in systemic juvenile idiopathic arthritis: From multiple centers

  2025cites this paper
• Makrophagenaktivierungssyndrom: Notfall mit therapeutischen Herausforderungen

  2025cites this paper
• Canakinumab for systemic-onset juvenile idiopathic arthritis/Still’s disease—effectiveness and safety data from the BiKeR registry

  2025cites this paper
• A case of adult-onset Still disease complicated by macrophage activation syndrome and toxic epidermal necrolysis

  2025cites this paper
• Distinct natural killer cell signature in still's disease: Insights from a multinational immunome project consortium for autoinflammatory disorders.

  2025cites this paper
• Autoinflammatorische Syndrome

  2025cites this paper
• The EULAR points to consider regarding the development of criteria for the assessment of the disease activity in adult-onset Still’s disease

  2025cites this paper
• Adult‐Onset Still's Disease Complicated by Secondary Hemophagocytic Lymphohistiocytosis: A Case Report

  2025cites this paper
• Novel insights into the biology of childhood arthritis- lessons learned from the synovium

  2025cites this paper
• From infectious disease specialist to rheumatologist — difficulties in diagnosing autoinflammatory diseases using adult-onset Still’s disease an example

  2025cites this paper
• Non-Classical Complications of Adult-Onset Still’s Disease: A Multicenter Spanish Study

  2025cites this paper
• Initiate treatment with inflammatory modulators early in adult-onset Still’s disease

  2025influential citation
• Uncertainty in the diagnosis and prognosis of adult-onset Still's disease.

  2025cites this paper
• Early identification of macrophage activation syndrome in adult-onset Still’s disease: a case report and literature review

  2025cites this paper
• Patients with Adult-Onset Still’s Disease in Germany: A Retrospective Analysis of Clinical Characteristics and Treatment Practices Ahead of the Release of the German Recommendations

  2025influential citation
• Toward a personalized therapy of still’s disease based on immunologic endotypes: a narrative review

  2025cites this paper